Abeona Therapeutics Inc. (NASDAQ:ABEO) gained volume of 2.01 million shares and the average volume of the stock remained 1.06 million shares. The 52 week range of the stock remained $4.55 – $22.75 and today’s day range was $15.65 – $16.60. The stock opened the session at $15.90 but then moved to $16.55, at recent check. At that price, the stock was showing a positive performance of 4.09%.
Abeona Therapeutics Inc. (ABEO), a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company’s lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.
ARCA biopharma, Inc. (NASDAQ:ABIO) was trading with a volume of 3.99 million shares versus the average volume of the stock 705.23K shares. The stock increased +8.96% and was recently trading at $0.56. The market capitalization of the stock remained 7.76 million. The EPS of the stock was -1.54.
ARCA biopharma, Inc. (ABIO) on May 29, 2018 announced that data from the GENETIC-AF clinical trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European Society of Cardiology Heart Failure 2018 World Congress on Sunday May 27, 2018. William T. Abraham, M.D., Professor of Medicine, Physiology and Cell Biology and Director, Division of Cardiovascular Medicine at the Ohio State University presented the data.
In the overall study population of heart failure patients who were at high risk for recurrent atrial fibrillation (AF), pharmacogenetic guided GencaroTM did not reduce AF/AFL/ACM recurrence compared to the active comparator TOPROL-XL. However, in U.S. patients (48% of the entire cohort), a trend for potential benefit in favor of Gencaro (approximately 30% risk reduction over TOPROL-XL), was observed for the primary endpoint of all-cause mortality (ACM) or time to recurrence of AF or atrial flutter (AFL). A trend for potential benefit in favor of Gencaro was also observed in a subset of patients from the U.S., Canada and Europe who underwent continuous heart rhythm monitoring with Medtronic implanted devices (approximately 25% risk reduction over TOPROL-XL). Safety data indicated that Gencaro was well-tolerated in the AF-HFrEF population investigated with a safety profile similar to TOPROL-XL.
In the current trading day, Joey New York, Inc. (OTCBB:JOEY) increased +18.89% to move at $0.107. The volume of the stock was 29,252.00 shares and the average volume remained 26,858.00 shares. The stock, at last check, has the day price range of $0.09 – $0.11. The market capitalization was recorded at 3.36 million.
Joey New York, Inc., through its subsidiary, RAR Beauty, LLC, manufactures and markets natural skin care and beauty products in the United States and Internationally. The company operates through The LABB, Aesthetic Beauty Bar; and Joey New York Cosmetics divisions. The LABB, Aesthetic Beauty Bar division provides injectable services, which eliminate unwanted wrinkles by performing Botox and filler injections. The company offers its products under the Joey New York brand. It offers its products through retailers, professional salons, spas, and beauty Websites.